Esophageal Squamous Cell Carcinoma
Conditions
Keywords
esophageal squamous cell carcinoma, neoadjuvant chemotherapy, albumin-bound paclitaxel, cisplatin
Brief summary
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma patients.
Detailed description
A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases.A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone.The neoadjuvant chemotherapy may improve overall survival. Neoadjuvant chemotherapy with administrations of paclitaxel combined with cisplatin or carboplatin has shown effectively.Nanoparticle albumin-bound (nab)-paclitaxel has better efficacy and practically eliminates the risk of hypersensitivity reactions associated with solvent-based paclitaxel.We try to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma patients.
Interventions
DRUGalbumin-bound paclitaxel plus cisplatin
neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histologic diagnosis of squamous cell carcinoma of esophagus. Preoperative stage Ⅱ-Ⅲ by endoscopic ultrasound, CT of the chest and abdomen,and esophagogram. * Age ranges from 18 to 70 years. * Patients must not have received any prior anticancer therapy. * Performance status of 0 to 1 * Estimated life expectancy of at least 6 months. * Tumor can be measured according to RECIST criteria * Signed informed consent document on file. * Females with childbearing potential must have a negative serum pregnancy * Adequate organ function including the following: Bone marrow: Absolute neutrophil count (ANC) greater than or equal 1.5×109/L Platelets greater than or equal 80×109/L Haemoglobin greater than or equal 80g/L Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN), Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN Renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment.
Exclusion criteria
* Carcinoma at the upper part of esophagus * Histologic diagnosis of adenocarcinoma of esophagus. * Prior treatment for esophageal cancer. * Active infection. * Pregnant or breast feeding. * History of significant neurological or mental disorder, including seizures or dementia. * Prior invasive malignancy in 5 years (except for carcinoma in situ).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| response to induction therapy | 2 years | The response to induction therapy will be evaluated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of complete pathological response | 2 years | The rate of complete pathological response will be evaluated |
| R0 resection rate. | 2 years | Complete resection rate to pre-operative chemotherapy will be assessed |
| 3 years disease free and overall survival | 5 years | Three years disease free and overall survival will be evaluated. |
| safety and tolerability | From time of consent to last visit | To monitor the safety and tolerability by evaluation of the frequency, severity, and duration of treatment-emergent adverse events in all subjects |
Countries
China
Outcome results
None listed